...
首页> 外文期刊>Chemical Weekly >Ranbaxy buys US rights for skin disease drug of Canadian company
【24h】

Ranbaxy buys US rights for skin disease drug of Canadian company

机译:Ranbaxy收购加拿大公司皮肤病药物的美国专利权

获取原文
获取原文并翻译 | 示例
           

摘要

Ranbaxy Pharmaceuticals Inc(RPI),the US subsidiary of Ranbaxy has entered into an exclusive agreement with Canada's Cipher Pharmaceu-ticals Inc to develop and market Cipher's patented medicine'Cibeta-Isotretinoin'in the US market.RPI has paid Cipher an initial upfront milestone payment of l-mn(Rs.4.2-crore).The agreement includes additional pre-and post-commerciali-sation milestone payments of up to 23-mn(Rs.96.6-crore),contingent upon the achievement of certain milestone targets,a Cipher press release said.
机译:Ranbaxy在美国的子公司Ranbaxy Pharmaceuticals Inc(RPI)与加拿大Cipher Pharmaceuticals Inc.达成了独家协议,以在美国市场开发和销售Cipher的专利药“ Cibeta-异维A酸”。RPI已向Cipher支付了初步的里程碑支付l-mn(4.2千万卢比)。该协议包括多达23 mn(9.66千万卢比)的商业前和商业后里程碑付款,具体取决于实现某些里程碑目标,密码新闻稿说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号